Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 avr. 2024 13h08 HE | Source: Hagens Berman Sobol Shapiro LLP

AMLX 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action

SAN FRANCISCO, April 07, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
04 avr. 2024 12h50 HE | Source: Hagens Berman Sobol Shapiro LLP

AMLX 5-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action

SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class...
01 avr. 2024 12h59 HE | Source: Hagens Berman Sobol Shapiro LLP

Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO® ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman

SAN FRANCISCO, April 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
28 mars 2024 15h42 HE | Source: Hagens Berman Sobol Shapiro LLP

AMLX 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
25 mars 2024 14h33 HE | Source: Hagens Berman Sobol Shapiro LLP

Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO® Data – Hagens Berman

SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
22 mars 2024 09h21 HE | Source: Hagens Berman Sobol Shapiro LLP

Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO® ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman

SAN FRANCISCO, March 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
18 mars 2024 13h43 HE | Source: Hagens Berman Sobol Shapiro LLP

Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman

SAN FRANCISCO, March 18, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
13 mars 2024 18h50 HE | Source: Hagens Berman Sobol Shapiro LLP

Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman

SAN FRANCISCO, March 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
22 févr. 2024 18h57 HE | Source: Hagens Berman Sobol Shapiro LLP

Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO® Data – Hagens Berman

SAN FRANCISCO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class...
19 févr. 2024 12h40 HE | Source: Hagens Berman Sobol Shapiro LLP

Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO® Data – Hagens Berman

SAN FRANCISCO, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...

Page suivante